Full-Time
Business Architect
Platform Strategy and Transformation
Updated on 9/3/2026
Roche
1-10 employees
Global pharmaceuticals and diagnostics company
No salary listed
Sant Cugat del Vallès, Barcelona, Spain
In Person
Bachelor's, Master's
 Business & Strategy (1) |
|---|
Get referred to Roche
See people who can refer or advise you
- A Bachelor’s or Master’s degree in Computer Science or Engineering is required.
- At least 10+ years of experience in business or reference architecture and shared platform strategies is required.
- Deep knowledge of platform strategies, architectural governance, application programming interfaces, and shared services models is required.
- Familiarity with healthcare standards such as FHIR and HL7, compliance-based design, and industry regulations is required.
- Advanced consulting and communication skills and the ability to collaborate in cross-functional, global environments are required.
- Define and maintain the architecture roadmap and reference architecture, ensuring solutions are scalable, reliable, and aligned with the Roche Ecosystem strategy.
- Lead the delivery of actionable technology strategies and blueprints, guiding application integration through standard building blocks and reusable components.
- Drive platform-first approaches, identify technical gaps, and develop solutions for data interoperability and event-driven frameworks.
- Partner with engineers, product managers, and sales and medical teams to support strategic outcomes and ensure consistent technological implementation across customer-facing products.
- Analyze non-functional requirements, including security, performance, and scalability, and establish governance to reduce duplication and improve system robustness.
- Experience with cloud platforms such as AWS, Azure, or GCP and frameworks such as TOGAF or SAFe is highly valued.
Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.
Company Size
1-10
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1896
Get referred to Roche
See people who can refer or advise you
Simplify's Take
What believers are saying
- Roche reported 6% H1 2026 sales growth and reaffirmed mid-single-digit 2026 guidance.
- Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo drove H1 2026 growth.
- Alzheimer's and blood-cancer assets expanded in 2026, including pTau217, Susvimo, and SIM0660.
What critics are saying
- China diagnostics pricing reforms cut Roche diagnostics sales 15% in 2026 first half.
- Vabysmo missed U.S. expectations in July 2026, exposing brittle ophthalmology execution.
- Biosimilar erosion threatens Roche's aging biologics portfolio; Rituxan-style decline can hollow future cash flows.
What makes Roche unique
- Roche combines pharmaceuticals and diagnostics, leveraging 4,500 U.S. cobas analyzers for launches.
- Roche and Eli Lilly won FDA clearance for Elecsys pTau217 on September 9, 2026.
- Roche keeps buying pipeline optionality, signing Simcere SIM0660 and Treeline in 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Company News
Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.
Roche has committed $75 million upfront to acquire global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. The deal could reach $1.53 billion if the drug meets development, regulatory and commercial milestones, with additional tiered royalties. The agreement grants Roche exclusive development, manufacturing and commercialisation rights outside Simcere's retained markets. The upfront payment represents just 4.9% of the deal's total potential value. SIM0660 remains in preclinical stages. Roche generated CHF11.9 billion in core operating profit during the first half of the year. The company's US-quoted shares fell to $53.55 on Tuesday following the announcement.
CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.
Roche and Eli Lilly have received FDA clearance for a blood test that helps detect signs of Alzheimer's disease in people aged 55 and older experiencing cognitive decline. The Elecsys pTau217 test measures a blood biomarker to determine whether patients are likely to have brain changes associated with Alzheimer's. The test can be performed using more than 4,500 Roche laboratory analysers already installed across the United States. Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks, expanding access nationwide. Pricing has not been disclosed. The clearance follows European approval in May. Blood-based testing could provide a simpler alternative to existing methods like PET imaging and cerebrospinal fluid analysis, which can be expensive and invasive.
Roche has received FDA clearance for its Elecsys pTau217 blood test, marking the first FDA-cleared, single-biomarker blood test for assessing amyloid pathology associated with Alzheimer's disease. The test, developed with Eli Lilly, is designed for use in both primary and specialty care settings for individuals aged 55 and older showing signs of cognitive decline. The assay provides positive, intermediate, and negative result categories using validated clinical cutoffs across care settings. Results support both rule-in and rule-out assessment of amyloid pathology when interpreted alongside clinical information. The test will be available across Roche's installed base of over 4,500 cobas laboratory instruments in the US, enabling broad access through existing laboratory infrastructure. This clearance represents a significant advancement in Alzheimer's disease diagnostic capabilities.